Janus Henderson Group
ALDR

Janus Henderson Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Janus Henderson Group’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,047,267
Closed -$12.8M – 1362
2017
Q3 		$12.8M Sell
1,047,267
-2,180,291
-68% -$22.7M 0.01% 816
2017
Q2 		$37M Buy
+3,227,558
New +$59.7M 0.03% 594

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Janus Henderson Group's ALDR Position: Q4 2017 in Review

Janus Henderson Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 1,047,267 shares — an estimated $12.8M sold.

Janus Henderson Group first reported a position in ALDR in Q2 2017 and held it in 2 quarters. The position peaked at $37M in Q2 2017. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

  • Janus Henderson Group reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Janus Henderson Group sold 1,047,267 Alder Biopharmaceuticals shares in Q4 2017, an estimated $12.8M.
  • Janus Henderson Group first reported a position in Alder Biopharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Janus Henderson Group's Alder Biopharmaceuticals position peaked at $37M in Q2 2017.
  • 140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Janus Henderson Group's 13F filing for Q4 2017, filed 9 Feb 2018.